Gene therapy may represent a promising alternative treatment of epileptic patients who are resistant to conventional anti-epileptic drugs. Among the various approaches for the application of gene therapy in the treatment of CNS disorders, recombinant adeno-associated viral (AAV) vectors have been most widely used. Preclinical studies using a selection of "therapeutic" genes injected into the rodent brain to correct the compromised balance between inhibitory and excitatory transmission in epilepsy, showed significant reduction of seizures and inhibition of epileptogenesis. In particular, transduction of neuropeptide genes, such as galanin and neuropeptide Y (NPY) in specific brain areas in experimental models of seizures resulted in significant anticonvulsant effects. Recent findings showed a long-lasting NPY over-expression in the rat hippocampus by local application of recombinant AAV vectors associated with reduced generalization of seizures, delayed kindling epileptogenesis, and strong reduction of chronic spontaneous seizures. These results establish a proof-of-principle evidence of the efficacy of gene therapy as anticonvulsant treatment. Additional investigations are required to address safety concerns and possible side effects in more detail.

Neuropeptide Y overexpression using recombinant adenoassociated viral vectors / F. Noé, A. Frasca, C. Balducci, M. Carli, G. Sperk, F. Ferraguti, A. Pitkänen, R. Bland, H. Fitzsimons, M. During, A. Vezzani. - In: NEUROTHERAPEUTICS. - ISSN 1933-7213. - 6:2(2009 Apr 06), pp. 300-306. ((Intervento presentato al 4. convegno Workshop on new horizons in the development of antiepileptic drugs: nontraditional approaches to treat epilepsy tenutosi a Dublin (Ireland) nel 2008.

Neuropeptide Y overexpression using recombinant adenoassociated viral vectors

A. Frasca;
2009

Abstract

Gene therapy may represent a promising alternative treatment of epileptic patients who are resistant to conventional anti-epileptic drugs. Among the various approaches for the application of gene therapy in the treatment of CNS disorders, recombinant adeno-associated viral (AAV) vectors have been most widely used. Preclinical studies using a selection of "therapeutic" genes injected into the rodent brain to correct the compromised balance between inhibitory and excitatory transmission in epilepsy, showed significant reduction of seizures and inhibition of epileptogenesis. In particular, transduction of neuropeptide genes, such as galanin and neuropeptide Y (NPY) in specific brain areas in experimental models of seizures resulted in significant anticonvulsant effects. Recent findings showed a long-lasting NPY over-expression in the rat hippocampus by local application of recombinant AAV vectors associated with reduced generalization of seizures, delayed kindling epileptogenesis, and strong reduction of chronic spontaneous seizures. These results establish a proof-of-principle evidence of the efficacy of gene therapy as anticonvulsant treatment. Additional investigations are required to address safety concerns and possible side effects in more detail.
adeno-associated viral vectors; anticonvulsant; gene therapy in epilepsy; neuropeptides; temporal lobe epilepsy; adenoviridae; animals; DNA, recombinant; epilepsy; genetic therapy; humans; neuropeptide Y; genetic vectors; pharmacology; neurology (clinical); pharmacology (medical)
Settore BIO/13 - Biologia Applicata
6-apr-2009
Article (author)
File in questo prodotto:
File Dimensione Formato  
Noè et al., 2009.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.12 MB
Formato Adobe PDF
1.12 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/532148
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 31
social impact